A tough transition

Nature

Volumn 449, Issue 7159, 2007, Pages 160-163

  Singer, Peter A ^a   Berndtson, Kathryn ^a   Tracy, C Shawn ^a   Cohen, Emma R M ^a   Masum, Hassan ^a   Lavery, James V ^b   Daar, Abdallah S ^a  

^a McLaughlin Rotman Centre for Global Health   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

BIOTECHNOLOGY; DEVELOPING WORLD; HEALTH CARE; HUMAN IMMUNODEFICIENCY VIRUS;

AFRICA; BIOTECHNOLOGY; CAMBODIA; CAMEROON; DEVELOPING COUNTRY; DRUG COST; ECONOMICS; GENETICALLY MODIFIED FOOD; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNGER; NIGERIA; POLITICAL SYSTEM; PRIORITY JOURNAL; REVIEW; SCIENCE; SOCIAL ASPECT; UNITED STATES; ZAMBIA;

AFRICA;

EID: 34548615665     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/449160a     Document Type: Review

References (12)

1. Daar, A. S. et al. Nature Genet. 32, 229-232 (2002).
2. Morel, C. et al. Science 309, 401-404 (2005).
3. Maitland, C. AI Soc. 13, 341-356 (1999).
4. Geroski, P. A. Res. Pol. 29, 603-625 (2000).
5. Keller, W. J. Econ. Lit. XLII, 752-782 (2004).
6. Widdus, R. & White, K. Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships (Initiative on Public-Private Partnerships for Health, Global Forum for Health Research, Geneva, 2004).
7. Commission on Intellectual Property Rights, Innovation and Public Health. Public Health Innovation and Intellectual Property Rights (World Health Organization, Geneva, 2006).
8. Stoneman, P. & Diederen, P. Econ. J. 104, 918-930 (1994).
9. Singh, J. A. & Mills, E. J. PLoS Med. 2, e234 (2005).
10. Mitchell, P. Nature Biotechnol. 21, 6 (2003).
11. Frew, S. E. et al. Nature Biotechnol. 25, 403-417 (2007).
12. Thorsteinsdóttir, H. et al. Nature Biotechnol. 22, DC48-DC52 (2004).